Sabatier-Vincent M, Charles J, Pinel N, Challende I, Claeys A, Leccia MT. [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].
Ann Dermatol Venereol 2014;
141:689-93. [PMID:
25442474 DOI:
10.1016/j.annder.2014.09.024]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2014] [Revised: 07/17/2014] [Accepted: 09/01/2014] [Indexed: 12/15/2022]
Abstract
BACKGROUND
Acantholytic dyskeratosis under BRAF inhibitors are dermatological diseases rarely reported to date.
PATIENTS AND METHODS
We report 2 cases of acantholytic dyskeratosis, reaching the trunk and the seborrheic zones, not itchy, appeared one month after the introduction of vemurafenib. The histological analysis was typical of a "Grover-like rash" for the 2 patients.
DISCUSSION
The appearance of acantholytic dyskeratosis under vemurafenib, a BRAF inhibitor, seems related with a paradoxical activation of the MAP-kinases pathway and with a growth acceleration of lesions in which RAS mutations of keratinocytes. Theses dermatoses seem also to occur with dabrafenib.
CONCLUSION
The patients treated by BRAF inhibitors (vemurafenib and dabrafenib) can present acantholytic dyskeratosis. The arisen of this mild dermatosis does not question, of course, the continuation of the treatment. These cutaneous manifestations can be managed with emollients.
Collapse